NCT07138885: A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

Sponsor: Sun Yat-sen University. Phase: PHASE2. Conditions: Hepatocellular Carcinoma (HCC), Second Line Treatment